SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-003764
Filing Date
2023-01-19
Accepted
2023-01-19 16:01:32
Documents
12
Period of Report
2023-01-12
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea171706-8k_emmaus.htm   iXBRL 8-K 32598
  Complete submission text file 0001213900-23-003764.txt   202213

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE emma-20230112.xsd EX-101.SCH 3242
3 XBRL LABEL FILE emma-20230112_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE emma-20230112_pre.xml EX-101.PRE 22369
6 EXTRACTED XBRL INSTANCE DOCUMENT ea171706-8k_emmaus_htm.xml XML 3291
Mailing Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503
Business Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503 310-214-0065
Emmaus Life Sciences, Inc. (Filer) CIK: 0000822370 (see all company filings)

IRS No.: 870419387 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35527 | Film No.: 23537432
SIC: 2834 Pharmaceutical Preparations